Riverbridge Partners LLC lessened its holdings in shares of Stevanato Group S.p.A. (NYSE:STVN – Free Report) by 5.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 673,148 shares of the company’s stock after selling 42,011 shares during the period. Riverbridge Partners LLC owned 0.22% of Stevanato Group worth $9,256,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. GW&K Investment Management LLC lifted its stake in Stevanato Group by 76.2% in the 4th quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock worth $49,000 after purchasing an additional 1,055 shares in the last quarter. State of Wyoming increased its holdings in shares of Stevanato Group by 39,216.7% in the second quarter. State of Wyoming now owns 2,359 shares of the company’s stock valued at $58,000 after purchasing an additional 2,353 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Stevanato Group in the third quarter valued at approximately $68,000. Tower Research Capital LLC TRC lifted its position in Stevanato Group by 1,268.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock worth $112,000 after buying an additional 4,250 shares in the last quarter. Finally, Van Berkom & Associates Inc. lifted its position in Stevanato Group by 55.4% during the fourth quarter. Van Berkom & Associates Inc. now owns 5,617 shares of the company’s stock worth $113,000 after buying an additional 2,002 shares in the last quarter.
Stevanato Group Price Performance
STVN stock opened at €16.79 on Wednesday. Stevanato Group S.p.A. has a 52-week low of €12.89 and a 52-week high of €28.00. The company has a quick ratio of 1.11, a current ratio of 1.63 and a debt-to-equity ratio of 0.21. The stock has a market cap of $5.08 billion, a price-to-earnings ratio of 28.46, a price-to-earnings-growth ratio of 1.56 and a beta of 0.78. The business has a fifty day moving average of €17.27 and a two-hundred day moving average of €17.33.
Stevanato Group Cuts Dividend
The business also recently announced an annual dividend, which will be paid on Wednesday, July 29th. Shareholders of record on Thursday, June 11th will be paid a dividend of $0.054 per share. This represents a yield of 31.0%. The ex-dividend date of this dividend is Thursday, June 11th.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the company. Citigroup dropped their target price on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, March 5th. KeyCorp reduced their price target on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Wolfe Research began coverage on shares of Stevanato Group in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $21.00 price target on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Stevanato Group in a report on Monday, June 8th. Finally, TD Cowen upgraded shares of Stevanato Group to a “strong-buy” rating in a research report on Wednesday, June 17th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.
View Our Latest Research Report on Stevanato Group
Stevanato Group Company Profile
Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.
In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.
See Also
- Five stocks we like better than Stevanato Group
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Want to see what other hedge funds are holding STVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stevanato Group S.p.A. (NYSE:STVN – Free Report).
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
